Environmental Health in Emergencies and Disasters
Chapter 10
2nd. edition
The new edition has been developed to make widely available to programme managers, health care workers in endemic settings, academic researchers, and other key partners, a concise source of information on strategies for MMDP for LF. It is a product of efforts to elaborate and concepts ...and approaches introduced in the previous edition, with a focus on ensuring that countries have the tools necessary to provide the essential package of care for LF.
more
Accessed 3rd of October 2015
These forms are intended only for clinicians and nurses taking care of patients with Ebola virus disease. They provide standardized information that needs to be collected by the clinicians at admission time, every day and at time of discharge.
These forms are intended only for clinicians and nurses taking care of patients with Ebola virus disease. They provide standardized information that needs to be collected by the clinicians at admission time, every day and at time of discharge.
РУКОВОДСТВО ПО ВЕДЕНИЮ НАИБОЛЕЕ РАСПРОСТРАНЕННЫХ БОЛЕЗНЕЙ ДЕТСКОГО ВОЗРАСТА
Второе издание
Данная публикация является вторым изданием Карманного справочника... «Оказание стационарной помощи детям», первое издание которого было выпущено Всемирной организацией здравоохранения (ВОЗ) в 2005 году. В справочнике собрана информация из обновленных руководств ВОЗ по ведению распространенных заболеваний детского возраста в стационарах первого уровня в странах с низкой обеспеченностью ресурса- ми. Справочник содержит современные клинические рекомендации, основанные на фактических данных, которые могут быть использованы врачами в их повседневной работе в больницах, где есть возможность проведения элементарных лабораторных исследований и имеются в наличии недорогие лекарственные средства.
Special attention is drawn to the following sections, which are particulary relevant within the COVID-19 context:
Chapter 4: information on cough and difficulty in breathing, pneumonia and bronchiolitis;
Chapter 10: information on essential supportive care including feeding, fluid and oxygen provision;
Annex 1: information on related practical procedures.
more
Overview: In this course, you will learn about the causes of unsafe injection practices, how to safely give injections, and how to safely dispose of needles and other sharps. You will also learn what to do when needle-stick injuries occur, how to manage potential exposures, and ways to protect yours...elf, the staff and patients in your facility, and your community.
Course duration: Approximately 2 hours.
more
Expert Consensus Report for Emergency Centres in
Western Cape
Compilation of campaign materials
Accessed on 29 September 2020
In order to meet changing global population needs and consumer expectations, healthcare systems worldwide are under transformation and face restructuring. As systems adapt and shift their emphasis in response to the disparate requests for healthcare services, oppor-tunities emerge for nurses, especi...ally the APN, to meet these demands and unmet needs (Bryant-Lukosius et al. 2017; Carryer et al. 2018; Cassiani & Zug 2014; Cooper & Docherty 2018; Hill et al. 2017; Maier et al.2017). In 2002, the International Council of Nurses (ICN) pro-vided an official position on Advanced Practice Nursing (ICN 2008a). Since that time, worldwide development has increased significantly and simultaneously this field of nursing has matured. ICN felt that a review of its position was needed to assess the relevance of the definition and characteristics offered in 2002. This guid-ance paper defines diverse elements such as assump-tions and core components of the APN. The attributes and descriptors presented in this paper are intended to promote a common vision to continue to enable a greater understanding by the international nursing and healthcare communities for the development of roles commonly identified as Clinical Nurse Specialist (CNS) and Nurse Practitioner (NP).
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more